UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  October 6, 2008

OCCULOGIX, INC.
(Exact name of Registrant as specified in its Charter)
 
 
Delaware
000 51030
59-343-4771
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)


2600 Skymark Avenue, Unit 9, Suite 201
Mississauga, Ontario L4W 5B2
(Address of principal executive offices)
Registrant’s telephone number, including area code:   (905) 602-0887

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


 
 

 

ITEM 1.01 Entry into a Material Definitive Agreement

On October 6, 2008, OccuLogix, Inc. (the “Company”) issued a press release announcing that, among other transactions, it had completed the acquisition of the minority ownership interest in OcuSense, Inc. (“OcuSense”) that the Company did not already own and the private placement of U.S.$2,173,000 amount of shares of the Company’s common stock (the “Common Stock”).

The acquisition of the minority ownership interest in OcuSense was effected pursuant to the Agreement and Plan of Merger and Reorganization, dated April 22, 2008, by and among the Company, OcuSense Acquireco, Inc., a wholly-owned subsidiary of the Company (“Merger Sub”) and OcuSense, as amended by the Amending Agreement, dated as of July 28, 2008, by and among OccuLogix, Merger Sub and OcuSense (as amended, the “Merger Agreement”).  As of October 6, 2008, the Company, Merger Sub and OcuSense entered into a further agreement (the “Second Merger Agreement Amending Agreement”), amending the Merger Agreement for, among other purposes, to make explicit the consequence of the Reverse Stock Split (defined below) on the numbers of shares of the Common Stock underlying the outstanding stock options of OcuSense, which were assumed by OccuLogix pursuant to the Merger Agreement, and on their respective exercise prices.  A copy of the Second Merger Agreement Amending Agreement is attached to this Current Report on Form 8-K as Exhibit 10.1.

The private placement of U.S.$2,173,000 amount of shares of the Common Stock was effected pursuant to the Securities Purchase Agreement, dated as of May 19, 2008, by and among the Company, Marchant Securities Inc. (“Marchant”) and the investors listed on the Schedule of Investors attached thereto as Exhibit A, as amended by the Amending Agreements, each dated as of August 29, 2008, by and among the Company, Marchant and each of the investors listed in the Schedule of Investors attached thereto as Exhibit A (as amended, the “Securities Purchase Agreement”).  As of October 1, 2008, the Company, Marchant and the investors party to the Securities Purchase Agreement entered into a further agreement (the “Second SPA Amending Agreement”), amending the Securities Purchase Agreement, for among other purposes, to revise the closing and funding mechanics of the transactions contemplated thereunder.  A copy of the Second SPA Amending Agreement is attached to this Current Report on Form 8-K as Exhibit 10.2.

ITEM 2.01 Completion of Acquisition or Disposition of Assets

On October 6, 2008, pursuant to the Merger Agreement, as amended by the Second Merger Agreement Amending Agreement, the Company completed the acquisition of the minority ownership interest in OcuSense that it did not already own.  Prior to such acquisition, the Company had owned 50.1% of the capital stock of OcuSense on a fully diluted basis and 57.62% on an issued and outstanding basis.  The acquisition was effected pursuant to a statutory merger of Merger Sub with and into OcuSense, with the separate corporate existence of Merger Sub ceasing and OcuSense continuing as the surviving corporation.

As consideration for the minority ownership interest in OcuSense, the Company issued an aggregate of 79,248,175 shares of the Common Stock to the minority stockholders of OcuSense.  The quantum of the merger consideration was based on a full-enterprise valuation of OcuSense of U.S.$18,000,000, determined in good faith by the respective boards of directors of the Company and OcuSense, and a deemed value of U.S.$0.10 per share of the Common Stock, which was reflective of the per share average trading price of the Common Stock on NASDAQ during the period of negotiation of the merger consideration.

 
- 2 -

 

Eric Donsky, a past and current director of OcuSense, has been a director of the Company since September 30, 2008 and the Company’s Chief Executive Officer as of October 6, 2008.  Mr. Donsky also was a minority stockholder of OcuSense.  He received, as his pro rata share of the merger consideration, 45,104,892 shares of the Common Stock which, upon the Reverse Split (defined below), was combined into 1,804,196 shares of the Common Stock.

Richard L. Lindstrom, a director of the Company since December 2004, was also a minority stockholder of OcuSense.  He received, as his pro rata share of the merger consideration, 2,148,438 shares of the Common Stock which, upon the Reverse Split (defined below), was combined into 85,938 shares of the Common Stock.  Dr. Lindstrom also held stock options of OcuSense, exercisable into an aggregate of 6,290 shares of OcuSense’s common stock at an exercise price of U.S.$4.80 per share of OcuSense’s common stock.  Pursuant to the Merger Agreement, these stock options were assumed by the Company, upon which assumption they became exercisable into an aggregate of 361,183 shares of the Common Stock with a per share exercise price of U.S.$0.09.  Upon the Reverse Split (defined below), these stock options were combined into stock options exercisable into 14,448 shares of the Common Stock with a per share exercise price of U.S.$2.25.

Donald Rindell, a director of the Company since September 30, 2008 and a past and current director of OcuSense, held stock options of OcuSense, exercisable into an aggregate of 13,748 shares of OcuSense’s common stock at an exercise price of U.S.$4.80 per share of OcuSense’s common stock.  Pursuant to the Merger Agreement, these stock options were assumed by the Company, upon which assumption they became exercisable into an aggregate of 789,436 shares of the Common Stock with a per share exercise price of U.S.$0.09.  Upon the Reverse Split (defined below), these stock options were combined into stock options exercisable into 31,578 shares of the Common Stock with a per share exercise price of U.S.$2.25.

ITEM 3.02 Unregistered Sales of Equity Securities

In connection with the acquisition by the Company, pursuant to the Merger Agreement, as amended by the Second Merger Agreement Amending Agreement, of the minority ownership interest in OcuSense that it did not already, the Company issued an aggregate of 79,248,175 shares of the Common Stock.  (See Items 1.01 and 2.01.)  Pursuant to the Securities Purchase Agreement, as amended by the Second SPA Amending Agreement, the Company sold an aggregate of 21,730,000 shares of the Common Stock to the investors party thereto at a per share price of U.S.$0.10, for gross aggregate proceeds of U.S.$21,730,000.  (See Item 1.01.)

As announced in the Company’s press release of October 6, 2008, the Company prepaid its then outstanding U.S.$6,703,500 aggregate principal amount bridge loan (the “Bridge Loan”) to the lenders thereof by issuing to them shares of the Common Stock at a per share price of U.S.$0.085.  In connection with the pre-payment of the Bridge Loan (plus accrued but unpaid interest), the Company issued to the lenders thereof an aggregate of 82,611,413 shares of the Common Stock.

 
- 3 -

 

On October 6, 2008, the Company also paid U.S.$481,200 of the commission remaining owing for placement agency services rendered by Marchant by issuing to it shares of the Common Stock at a per share price of U.S.$0.10.  In connection with such payment, the Company issued to Marchant an aggregate of 4,812,000 shares of the Common Stock.

All of these issuances of shares of the Common Stock were made in reliance upon the exemption from registration afforded by Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”), Rule 506 of Regulation D, as promulgated by the U.S. Securities and Exchange Commission (the “SEC”) under the Securities Act, and Rule 903 of Regulation S, as promulgated by the SEC under the Securities Act, as well as the exemptions from the prospectus and registration requirements afforded by National Instrument 45-106—Prospectus and Registration Exemptions in Canada and comparable exemptions in certain other foreign jurisdictions.  All of the parties to whom shares of the Common Stock have been issued in the above-described transactions were either “accredited investors” or, in the case of two minority stockholders of OcuSense, represented by a “purchaser representative”, in each case as such term is defined in Rule 501 of Regulation D, as promulgated by the SEC under the Securities Act, and no form of general solicitation or general advertising was used in connection with these transactions.
 
ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

As announced in the Company’s press release of October 6, 2008, Elias Vamvakas has stepped down as the Company’s Chief Executive Officer but remains the Chairman of the Board.  Mr. Donsky became the Company’s Chief Executive Officer on October 6, 2008, upon the closing of the transactions contemplated by the Merger Agreement, as amended by the Second Merger Agreement Amending Agreement.

Mr. Donsky, 43, has 15 years of experience in the development of early-stage biotechnology and life science companies, as a founder and senior manager.  Mr. Donsky has been the Chairman and Chief Executive Officer of OcuSense since January 2003.  He is also a principal of Molecular Biosciences, a life science incubator and consulting practice.  Previously, he was the founding Chief Executive Officer of Zolaris Biosciences, Inc., an early-stage biotechnology company focused on the discovery and development of therapeutics for the treatment of rheumatoid arthritis, multiple sclerosis and infectious diseases.  Prior to his tenure at Zolaris Biosciences, Inc., Mr. Donsky was the founding Chief Executive Officer of Applied CarboChemicals, Inc. (“ACC”), a biotechnology company focused on the commercial development of novel fermentation processes capable of manufacturing unique compounds that have application in the food, chemical and pharmaceutical industries.  ACC currently has manufacturing operations and several products on the market.  Mr. Donsky graduated from Boston University in 1987 with a B.S. in Business Administration.

 
- 4 -

 

At the present time, Mr. Donsky’s compensation consists of a base salary of U.S.$260,000 per annum.

As of October 6, 2008, Robert Walder became the Company’s Vice President, Operations.  He previously had been serving as OcuSense’s Vice President, Operations and continues to hold that office.
 
As of October 6, 2008, Robert Walder, 57, became the Company’s Vice President, Operations.  He joined OcuSense in July 2008 as a consultant and, shortly thereafter, became OcuSense’s Vice President, Operations, and continues to hold that office today.  He is also a principal in The Samaritan Group, a consulting group specializing in medical services.

Mr. Walder has over 30 years of healthcare and management experience, both as a caregiver and a senior manager.  Previously, he was the Vice President of Clinical Operations of Digirad, Corp. (“Digirad”) a developer of solid state gamma cameras and the largest provider of in-office cardiology imaging services.  Prior to his tenure at Digirad, Mr. Walder was the Business Unit Manager for Abbott Laboratories, a global organization that develops, manufactures and distributes healthcare products and pharmaceuticals.  Mr. Walder graduated from California State College with a Bachelors degree in Electrical Engineering, the University of Southern California with a Baccalaureate in Medicine and the University of Phoenix with degrees in Business Administration and Management.

At the present time, Mr. Walder’s compensation consists of a base salary of U.S.$145,000 per annum.
 
ITEM 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

On October 1, 2008, the Company filed, with the Secretary of State of the State of Delaware (the “Delaware Secretary of State”) a Certificate of Amendment to its Amended and Restated Certificate of Incorporation in order to increase the number of authorized shares of the Common Stock, from 75,000,000 to 500,000,000.  A copy of such Certificate of Amendment is attached to this Current Report on Form 8-K as Exhibit 3.1.

On October 7, 2008, the Company filed, with the Delaware Secretary of State, a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, as amended, in order to (i) provide for a recapitalization in which the issued and outstanding shares of the Common Stock was reverse split in a ratio of 1:25 (the “Reverse Split”) and (ii) upon the effectiveness of the Reverse Split, decrease the number of authorized shares of the Common Stock from 500,000,000 to 40,000,000.  A copy of such Certificate of Amendment is attached to this Current Report on Form 8-K as Exhibit 3.2.

On October 7, 2008, following the filing of such Certificate of Amendment, the Company filed, with the Delaware Secretary of State, a Restated Certificate of Incorporation in order to restate the Company’s Amended and Restated Certificate of Incorporation, as amended.  A copy of such Restated Certificate of Incorporation is attached to this Current Report on Form 8-K as Exhibit 3.3.

ITEM 9.01 Financial Statements and Exhibits

(a) Financial statements of businesses acquired

The required financial statements of OcuSense, Inc. will be filed by amendment to this Current Report on Form 8-K on or prior to December 19, 2008.

(b) Pro forma financial information

The required pro forma financial information will be filed by amendment to this Current Report on Form 8-K on or prior to December 19, 2008.

(d) Exhibits

Certificate of Amendment of OccuLogix, Inc., filed with the Secretary of State of the State of Delaware on October 1, 2008.

 
- 5 -

 

Certificate of Amendment of OccuLogix, Inc., filed with the Secretary of State of the State of Delaware on October 7, 2008.

Restated Certificate of Incorporation of OccuLogix, Inc., filed with the Secretary of State of the State of Delaware on October 7, 2008.

Second Amending Agreement, dated as of October 6, 2008, by and among OccuLogix, Inc., OcuSense Acquireco, Inc. and OcuSense, Inc.

Second Amending Agreement, dated as of October 1, 2008, by and among OccuLogix, Inc., Marchant Securities Inc. and the investors listed on the Schedule of Investors attached thereto as Exhibit A.

Press Release of OccuLogix, Inc. dated October 6, 2008.

Press Release of OccuLogix, Inc. dated October 7, 2008.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
   
OCCULOGIX, INC.
     
Date:   October 9, 2008
   
 
By:
/s/Suh Kim
   
Suh Kim
   
General Counsel
 
 
- 6 -


EXHIBIT 3.1
 
Delaware
The First State
 
I,  harriet smith windsor,  secretary of state of the state of delaware,   do hereby certify the attached is a true and correct copy of the certificate of amendment of  "occulogix,   inc.",  filed in this office on the first day of october, a.d,  2008, at 1:59 o'clock p.m.
 
a filed copy of this certificate has been forwarded to the kent county recorder of deeds.

 
 
 
 
 

 
-1-

 
 
 
State of Delaware
 
Secretary of State
 
Division or Corporations
 
Delivered 01:55 PM 10/01/2008
 
FILED 01:59 PM 10/01/2008
 
SRV 081003569 - 3520855 FILE

CERTIFICATE OF AMENDMENT
OF THE
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
OCCULOGIX, INC.
(the "Corporation")

Pursuant to the provisions of Section 242 of the General Corporation Law of the State of Delaware, the Corporation adopts the following Certificate of Amendment to its Amended and Restated Certificate of Incorporation:
 
1.                             The amendment to the existing Amended and Restated Certificate of Incorporation being effected hereby is to delete the first paragraph of Article IV in its entirety and to substitute in its place the following:
 
*******************************************************
 
The Corporation is authorized to issue two classes of stock to be designated, respectively, "Common Stock" and "Preferred Stock." The total number of shares of all classes of capital stock which the Corporation shall have authority to issue is five hundred ten million (510,000,000), of which five hundred million (500,000,000) shares, par value $0.001 per share, shall be common stock (the "Common Stock") and ten million (10,000,000) shares, par value $0.001 per share, shall be preferred stock (the "Preferred Stock").
 
*******************************************************
 
2.                             This Certificate of Amendment to the Amended and Restated Certificate of Incorporation was approved by written consent of the board of directors and by the stockholders of this Corporation at a meeting thereof duly called and held on September 30, 2008.
 
3.                             This Certificate of Amendment to the Amended and Restated Certificate of Incorporation shall be effective immediately upon filing by the Delaware Secretary of State.

 
-2-

 

IN WITNESS WHEREOF, the Corporation has executed this Certificate of Amendment to the Amended and Restated Certificate of Incorporation as of the 1st day of October, 2008.


 
/s/ Elias Vamvakas
 
Name:     Elias Vamvakas
 
Title:       Chairman of the Board, Chief
 
Executive Officer and Secretary
 
 
-3-


EXHIBIT 3.2
 
DELAWARE
The First State
 

I,  HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "OCCULOGIX, INC.", FILED IN THIS OFFICE ON THE SEVENTH DAY OF OCTOBER, A.D. 2008, AT 8:33 O'CLOCK A.M.
 
A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE KENT COUNTY RECORDER OF DEEDS.
 
 
 
 
 
 
 
 

 
 
-1-

 
 
 
State of Delaware
 
Secretary of State
 
Division of Corporations
 
Delivered 08:32 PM 10/07/2008
 
FILED 08:33 AM 10/07/2008
 
SRV 081016988 - 3520855 FILE

 
CERTIFICATE OF AMENDMENT
OF THE
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
OCCULOGIX, INC.
(the "Corporation")

Pursuant to the provisions of Section 242 of the General Corporation Law of the State of Delaware, the Corporation adopts the following Certificate of Amendment to its Amended and Restated Certificate of Incorporation:
 
1.                            T he following amendment to the existing Amended and Restated Certificate of Incorporation being effected hereby is to add the following new paragraph 6 at the end of Article IV, Section A:
 
*******************************************************
 
6.            Reverse St ock Split.
 
(a)           Upon this amendment becoming effective (the "Effective Time"), a one-for-twenty-five reverse stock split of each of the shares of common stock, $0.001 par value (the "Common Stock"), shall become effective, such that every twenty-five (25) shares of Common Stock either issued and outstanding or held by the Corporation as treasury stock immediately prior to the Effective Time, will be automatically reclassified and combined into one (1) share of such Common Stock. No fractional shares of Common Stock will be issued as a result of such reverse stock split. A holder of shares of Common Stock who otherwise would be entitled to a fractional share as a result of such reverse stock split will instead receive a whole share of Common Stock in lieu of such fractional share.
 
(b)         Each stock certificate that, immediately prior to the Effective Time, represented shares of Common Stock shall, from and after the Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of Common Stock into which the shares of Common Stock represented by such certificate shall have been reclassified, provided, however, that each holder of record of a certificate that represented shares of Common Stock shall receive, upon surrender of such certificate, a new certificate representing the number of whole shares of Common Stock into which the shares of Common Stock represented by such certificate shall have been reclassified.
 
*******************************************************

 
-2-

 

2.                              Further, the following amendment to the existing Amended and Restated Certificate of Incorporation being effected hereby is to delete the first paragraph of Article IV in its entirety and to substitute in its place the following:
 
********************************************************
 
The Corporation is authorized to issue two classes of stock to be designated, respectively, "Common Stock" and "Preferred Stock." The total number of shares of all classes of capital stock which the Corporation shall have authority to issue is fifty million (50,000,000), of which forty million (40,000,000) shares, par value $0.001 per share, shall be common stock (the "Common Stock") and ten million (10,000,000) shares, par value $0.001 per share, shall be preferred stock (the "Preferred Stock").
 
********************************************************
 
3.                             This Certificate of Amendment to the Amended and Restated Certificate of Incorporation was approved by written consent of the board of directors and by the stockholders of this Corporation at a meeting thereof duly called and held on September 30, 2008.
 
4.                             This Certificate of Amendment to the Amended and Restated Certificate of Incorporation shall be effective immediately upon filing by the Delaware Secretary of State.

 
-3-

 

IN WITNESS WHEREOF, the Corporation has executed this Certificate of Amendment to the Amended and Restated Certificate of Incorporation as of the 7th day of October, 2008.


 
/s/ Eric Donsky
 
Name: Eric Donsky
 
Title:   Chief Executive Officer
 
 
-4-


EXHIBIT 3.3
 
DELAWARE
The First State
 

i, harriet smith windsor,  secretary of state of the state of delaware, do hereby certify the attached is a true and correct copy of the restated certificate of "occulogix, inc." filed in this office on the seventh day of october, a.d. 2008, at   9:02 o'clock A.M.
 
A filed copy of this certificate has been forwarded to the kent county recorder of deeds.
 
 
 
 
 
 

 
 
 

 
 
 
State of Delaware
 
Secretary of State
 
Division of Corporations
 
Delivered 09:11 AM   10/07/2008
 
FILED 09:02 AM 10/07/2008
 
SRV 081017053 - 3520855 FILE

RESTATED CERTIFICATE OF INCORPORATION
 
OF
 
OCCULOGIX, INC.
 
OccuLogix, Inc., a corporation organized and existing under the laws of the State of Delaware (the "Corporation"), hereby certifies as follows:
 
FIRST: The name of the Corporation is OccuLogix, Inc. The Corporation was originally incorporated under the name Vascular Sciences Corporation in the State of Delaware on June 5, 2002. An Amended and Restated Certificate of Incorporation of the Corporation was filed in the office of the Delaware Secretary of State on July 16, 2002. An Amended and Restated Certificate of Incorporation of the Corporation was filed in the office of the Delaware Secretary of State on July 25, 2002. A Certificate of Amendment to the Certificate of Incorporation was filed in the office of the Delaware Secretary of State on August 29, 2003. On July 28, 2004, the Corporation changed its name by filing a Certificate of Amendment in the office of the Delaware Secretary of State. An Amended and Restated Certificate of Incorporation of the Corporation was filed in the office of the Delaware Secretary of State on December 8, 2004. A Certificate of Amendment to the Certificate of Incorporation was filed in the office of the Delaware Secretary of State on October 1, 2008. A Certificate of Amendment to the Certificate of Incorporation was filed in the office of the Delaware Secretary of State on October 7, 2008.
 
SECOND: This Restated Certificate of Incorporation was adopted by the Board of Directors of the Corporation in the manner prescribed by Section 245 of the Delaware General Corporation Law, and is as follows:
 
ARTICLE I
 
The name of this corporation is OccuLogix, Inc. (hereinafter sometimes referred to as the "Corporation").
 
ARTICLE II
 
The address of the Corporation's registered office in the State of Delaware is 160 Greentree Drive, Suite 101, Dover, Delaware, 19904, County of Kent. The name of its registered agent at such address is National Registered Agents, Inc.
 
ARTICLE III
 
The purpose of the Corporation is to engage in any lawful act or activity for which a corporation may be organized under the Delaware General Corporation Law (the "DGCL").

 
 

 

ARTICLE IV
 
The Corporation is authorized to issue two classes of stock to be designated, respectively, "Common Stock" and "Preferred Stock." The total number of shares of all classes of capital stock which the Corporation shall have authority to issue is fifty million (50,000,000), of which forty million (40,000,000) shares, par value $0.001 per share, shall be common stock (the "Common Stock") and ten million (10,000,000) shares, par value $0.001 per share, shall be preferred stock (the "Preferred Stock").
 
A.              COMMON STOCK.
 
1.              Divide nd Rights. The holders of shares of Common Stock may be entitled to receive as, if and when declared by the Board of Directors, out of the assets of the Corporation legally available therefor, such dividends as may be declared from time to time by the Board of Directors.
 
2.              Liquidation . Upon the voluntary or involuntary liquidation, sale, merger, consolidation, dissolution or winding up of the Corporation, holders of shares of Common Stock will be entitled to receive all assets of the Corporation available for distribution to its stockholders, subject to any preferential rights of any then outstanding Preferred Stock.
 
3.              Redemption . The Common Stock is not redeemable.
 
4.              Voting Rights . Except as otherwise required by law or this Restated Certificate of Incorporation, each holder of Common Stock shall have the right to one vote in respect of each share of Common Stock held, and shall be entitled to notice of any stockholders meeting in accordance with the By-Laws of the Corporation, and shall be entitled to vote upon such matters and in such manner as may be provided by law. There shall be no cumulative voting.
 
5.             Issuance. Additional shares of authorized Common Stock will be issued, as determined by the Board of Directors from time to time, without approval of holders of the Common Stock, except as may be required by applicable law or the rules of any stock exchange or automated quotation system on which the Corporation's securities may be listed or traded.
 
B.               PREFERRED STOCK.
 
1.             ISSUANCE. Shares of Preferred Stock may be issued from time to time in one or more series as may from time to time be determined by the Board of Directors, each of said series to be distinctly designated. All shares of any one series of the Preferred Stock shall be alike in every particular, except that there may be different dates from which dividends, if any, thereon shall be cumulative, if made cumulative. The voting powers, if any, and the designations, relative preferences, participating, optional or other special rights or privileges of each such series, and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding.

 
- 2 -

 

2.            AUTHORITY OF THE BOARD OF DIRECTORS. The Board of Directors is authorized, subject to limitations prescribed by law and the provisions of this Article FOURTH, to provide for the issuance of the shares of the Preferred Stock in series, and by filing a certificate pursuant to the applicable law of the State of Delaware, to establish from time to time the number of shares to be included in each such series, and to fix in the resolution or resolutions providing for the issue of such stock adopted by the Board of Directors of the Corporation the voting powers, if any, and the designations, relative preferences, participating, optional or other special rights or privileges, and the qualifications, limitations or restrictions of such series, including, but without limiting the generality of the foregoing, the following:
 
(a)           The distinctive designation of, and the number of shares of the Preferred Stock which shall constitute such series. The designation of a series of preferred stock need not include the words "preferred" or "preference" and may be designated "special" or other distinctive term. Unless otherwise provided in the resolution issuing such series, the number of shares of any series of the Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the Board of Directors in the manner prescribed by law;
 
(b)           The rate and times at which, and the terms and conditions upon which, dividends, if any, on the Preferred Stock of such series shall be paid, the extent of the preference or relation, if any, of such dividends to the dividends payable on any other class or classes, or series of the same or other classes of stock and whether such dividends shall be cumulative or non-cumulative and, if cumulative, the date from which such dividends shall be cumulative;
 
(c)           Whether the series shall be convertible into, or exchangeable for, at the option of the holders of the Preferred Stock of such series or the Corporation or upon the happening of a specified event, shares of any other class or classes or any other series of the same or any other class or classes of stock of the Corporation, and the terms and conditions of such conversion or exchange, including provisions for the adjustment of any such conversion rate in such events as the Board of Directors shall determine;
 
(d)           Whether or not the Preferred Stock of such series shall be subject to redemption at the option of the Corporation or the holders of such series or upon the happening of a specified event, and the redemption price or prices and the time or times at which, and the terms and conditions upon which, the Preferred Stock of such series may be redeemed;
 
(e)           The rights, if any, of the holders of the Preferred Stock of such series upon the voluntary or involuntary liquidation, merger, consolidation, distribution or sale of assets, dissolution or winding-up, of the Corporation;
 
(f)           The terms of the sinking fund or redemption or purchase account, if any, to be provided for the Preferred Stock of such series; and

 
- 3 -

 

(g)           Subject to subparagraph 5 of Paragraph C hereof, whether such series of the Preferred Stock shall have full, limited or no voting powers including, without limiting the generality of the foregoing, whether such series shall have the right, voting as a series by itself or together with other series of the Preferred Stock or all series of the Preferred Stock as a class, to elect one or more directors of the Corporation if there shall have been a default in the payment of dividends on any one or more series of the Preferred Stock or under such other circumstances and on such conditions as the Board of Directors may determine.
 
C.               OTHER PROVISIONS.
 
1.      No holder of any of the shares of any class or series of stock or of other securities of the Corporation shall have any preemptive right to purchase or subscribe for any unissued stock of any class or series or any additional shares of any class or series to be issued by reason of any increase of the authorized capital stock of the Corporation of any class or series, or bonds, certificates of indebtedness, debentures or other securities convertible into or exchangeable for stock of the Corporation of any class or series, or carrying any right to purchase stock of any class or series, but any such unissued stock, additional authorized issue of shares of any class or series of stock or securities convertible into or exchangeable for stock, or carrying any right to purchase stock, may be issued and disposed of pursuant to resolution of the Board of Directors to such persons, firms, corporations or associations (including such holders or others) and upon such terms as may be deemed advisable by the Board of Directors in the exercise of its sole discretion.
 
2.        The relative powers, preferences and rights of each series of the Preferred Stock in relation to the powers, preferences and rights of each other series of the Preferred Stock shall, in each case, be as fixed from time to time by the Board of Directors in the resolution or resolutions adopted pursuant to authority granted in Paragraph B hereof. The consent, by class or series vote or otherwise, of the holders of such of the series of the Preferred Stock as are from time to time outstanding shall not be required for the issuance by the Board of Directors of any other series of the Preferred Stock whether or not the powers, preferences and rights of such other series shall be fixed by the Board of Directors as senior to, or on a parity with, the powers, preferences and rights of such outstanding series, or any of them; provided, however, that the Board of Directors may provide in the resolution or resolutions as to any series of the Preferred Stock adopted pursuant to Paragraph B hereof, the conditions, if any, under which the consent of the holders of a majority (or such greater proportion as shall be fixed therein) of the outstanding shares of such series shall be required for the issuance of any or all other series of the Preferred Stock.
 
3.      Subject to the provisions of subparagraph 2 of this Paragraph C, shares of any series of the Preferred Stock may be issued from time to time as the Board of Directors of the Corporation shall determine and on such terms and for such consideration as shall be fixed by the Board of Directors.

 
- 4 -

 

4.      Shares of authorized Common Stock may be issued from time to time as the Board of Directors of the Corporation shall determine and on such terms and for such consideration as shall be fixed by the Board of Directors.
 
5.      The number of authorized shares of Common Stock and of the Preferred Stock, without a class or series vote, may be increased or decreased from time to time (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the stock of the Corporation entitled to vote thereon.
 
ARTICLE V
 
Unless and except to the extent that the By-Laws of the Corporation shall so require, the election of Board of Directors of the Corporation need not be by written ballot.
 
ARTICLE VI
 
The affirmative vote of the holders of at least a majority of the voting power of all shares of the Corporation entitled to vote generally in the election of Directors, voting together as a single class, shall be required in order for the stockholders to make, adopt, amend, alter, repeal and rescind any provisions of the Restated Certificate of Incorporation.
 
ARTICLE VII
 
The Board of Directors of the Corporation is expressly authorized to make, adopt, amend, alter, repeal, and rescind the By-Laws of the Corporation. Notwithstanding anything contained in this Restated Certificate of Incorporation to the contrary, the affirmative vote of the holders of at least a majority of the voting power of all shares of the Corporation entitled to vote generally in the election of Directors, voting together as a single class, shall be required in order for the stockholders to make, adopt, amend, alter, repeal and rescind any provisions of the By- Laws which is to the same effect as Article VII.
 
ARTICLE VIII
 
The Corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit of proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Corporation) by reason of the fact that the person, is or was a director, officer, employee or agent of the Corporation, or is or was serving a the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorney's fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the Corporation, and with respect to any criminal action or proceeding has no reasonable cause to believe the person's conduct wasunlawful. The termination of any action, suit, or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which the person reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that the person's conduct was unlawful

 
- 5 -

 

The right to indemnification conferred in the Article VIII shall be a contract right and shall include the right to be paid by the Corporation the expenses incurred in defending any such proceeding in advance of its final disposition; provided , however, that, if the DGCL requires, the payment of such expenses incurred by a director or officer in his or her capacity as a director or officer (and not in any other capacity in which service was or is rendered by such person while a director or officer, including, without limitation, service to an employee benefit plan) in advance of the final disposition of a proceeding, shall be made only upon delivery to the Corporation of an undertaking, by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be indemnified under this Article VIII or otherwise. The Corporation may, by action of its Board of Directors, provide indemnification to employees and agents of the Corporation with the same scope and effect as the foregoing indemnification of directors and officers.
 
If a claim under the preceding paragraph of this Article VIII is not paid in full by the Corporation within thirty (30) calendar days after a written claim has been received by the Corporation, the claimant may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim, and, if successful in whole or in part, the claimant shall be entitled to be paid also the expense of prosecuting such claim. It shall be a defense to any such action (other than an action brought to enforce a claim for expenses incurred in defending any proceeding in advance of its final disposition where the required undertaking, if any is required, has been tendered to the Corporation) that the claimant has not met the standards of conduct which make it permissible under the DGCL for the Corporation to indemnify the claimant for the amount claimed, but the burden of proving such defense shall be on the Corporation. Neither the failure of the Corporation (including its Board of Directors, independent legal counsel or stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because he or she has met the applicable standard of conduct set forth in the DGCL, nor an actual determination by the Corporation (including its Board of Directors, independent legal counsel or stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that the claimant has not met the applicable standard of conduct.
 
The right to indemnification and the payment of expenses incurred in defending a proceeding in advance of its final disposition conferred in this Article VIII shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, provision of the Restated Certificate of Incorporation, By-Laws, agreement, vote of stockholders or disinterested directors or otherwise.

 
- 6 -

 

The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any such expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the DGCL.
 
The Board of Directors may take such action as it deems necessary to carry out the indemnification provisions herein, including adopting procedures for determining and enforcing indemnification rights and purchasing insurance policies. The Board of Directors may also adopt By- Laws, resolutions or contracts implementing indemnification arrangements as may be permitted by law. Neither the amendment or repeal of these indemnification provisions, nor the adoption of any provision of this Restated Certificate of Incorporation inconsistent with these indemnification provisions, shall eliminate or reduce any rights to indemnification relating to the indemnities status or activities prior to such amendment, repeal or adoption.
 
A director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director's duty of loyalty to the Corporation or its stockholders; (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (iii) under Section 174 of the DGCL; or (iv) for any transaction from which the director derived an improper personal benefit. If the DGCL is amended after approval by the stockholders of this Article to authorize corporate action further eliminating or limiting the personal liability of directors then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL as so amended. Any repeal or modification of the foregoing provisions by the stockholders of the Corporation or the adoption of any provision which is inconsistent with this provision, shall not adversely affect any right or protection of a director of the Corporation existing at the time of such repeal or modification with respect to acts or omissions occurring prior to such repeal or modification.
 
ARTICLE IX
 
Any action required or permitted to be taken at any annual or special meeting of stockholders of the Corporation, may be taken without a meeting, without prior written notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation by delivery to its registered office in Delaware, its principal place of business, or an office or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded.

 
- 7 -

 

Meetings of stockholders may be held within or without the State of Delaware, as the By-Laws may provide. Special meetings of the stockholders may be called by the Chairman of the Board of Directors or by a majority of the Board of Directors or holders of at least two-thirds of our outstanding voting stock.
 
ARTICLE X
 
The Corporation elects not to be governed by Section 203 of the DGCL.
 
ARTICLE XI
 
The books of the Corporation may be kept (subject to any provision contained in the statutes) outside of Delaware at such place or places as may be designated from time to time by the Board of Directors or in the By-Laws of the Corporation.

 
- 8 -

 

IN WITNESS WHEREOF, OccuLogix, Inc., has caused this Restated Certificate of Incorporation to be signed as of October 7, 2008.
 
 
OCCULOGIX INC.
   
   
 
By: /s/ Eric Donsky
 
Name: Eric Donsky
 
Title: Chief Executive Officer
 
 


EXHIBIT 10.1
 
Execution Copy
 
SECOND AMENDING AGREEMENT

THIS SECOND AMENDING AGREEMENT (this “ Agreement ”) is made and entered into as of October 6 , 2008 by and among OccuLogix, Inc., a Delaware corporation (“ Parent ”), OcuSense Acquireco, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“ Merger Sub ”), and OcuSense, Inc., a Delaware corporation (the “ Company ”).
 
W I T NE S S E T H:
 
WHEREAS, the parties hereto have made and entered into that certain Agreement and Plan of Merger and Reorganization dated as of April 22, 2008 pursuant to which Parent will acquire the Company through the statutory merger of Merger Sub with and into the Company.
 
WHEREAS, such Agreement and Plan of Merger and Reorganization subsequently was amended by the Amending Agreement, dated as of July 28, 2008, by and among Parent, Merger Sub and the Company (as amended, the “ Merger Agreement ”).
 
WHEREAS, following the Effective Time, Parent will effect a recapitalization (the “ Reverse Stock Split ”) in which the issued and outstanding shares of Parent Common Stock will be reverse split in a ratio of 1:25 (the “ Reverse Split Ratio ”), upon the effectiveness of which the number of authorized shares of Parent Common Stock will decrease from 500,000,000 to 40,000,000.
 
WHEREAS, the parties hereto wish to amend the Merger Agreement further, as provided for herein, in order to give effect to their original intentions.
 
NOW, THEREFORE, in consideration of the foregoing premises, the mutual agreements and other covenants set forth herein, the mutual benefits to be gained by the performance thereof, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged and accepted, the parties hereto hereby agree as follows:
 
1.            Undefined Capitalized Terms .  Capitalized terms used herein, but not defined, have the respective meanings attributed to such terms in the Merger Agreement.
 
2.            Company Options .  Notwithstanding any contrary or inconsistent provision of the Merger Agreement, automatically and immediately upon the effectiveness of the Reverse Stock Split, the number of shares of Parent Common Stock into which the Company Options, to be assumed by Parent pursuant to Section 2.6(d) of the Merger Agreement, shall be exercisable shall be decreased by the Reverse Split Ratio and the per share exercise price of the assumed Company Options shall be increased by the Reverse Split Ratio.

 
 


3.            Conditions to Obligations of Each Party .  Section 7.1 of the Merger Agreement is hereby amended by deleting, in its entirety, Paragraph (d) thereof and replacing it with the following Paragraph (d):
 
(d)            Requisite Stockholder Approval .  This Agreement shall have been adopted, and the Merger shall have been approved, by the (i) holders of a majority of the outstanding shares of Company Common Stock, voting together as a separate class, (ii) holders of more than fifty percent of the outstanding shares of the Company’s Preferred Stock and (iii) holders of a majority of shares of Parent Common Stock represented at a duly constituted stockholders meeting of Parent.
 
4.            References to “this Agreement”, etc .  Where the context permits or requires, references to “this Agreement”, “herein”, “hereunder”, “hereof”, “hereto”, “herewith” and other similar expressions in the Merger Agreement shall be read and construed as references to the Merger Agreement, as amended hereby.
 
5.            Merger Agreement in Full Force and Effect .  The Merger Agreement remains in full force and effect, unamended, other than as specifically amended by this Agreement.
 
6.            Counterparts .  This Agreement may be executed in one or more counterparts (including by facsimile or e-mail transmission), all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each of the parties hereto and delivered to the other parties hereto, it being understood that all parties need not sign the same counterpart.
 
7.            Severability .  In the event that any provision of this Agreement or the application thereof becomes, or is declared by a court of competent jurisdiction to be, illegal, void or unenforceable, the remainder of this Agreement will continue in full force and effect and the application of such provision to the other persons or circumstances will be interpreted so as reasonably to effect the intent of the parties hereto.  The parties hereto further agree to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the economic, business and other purposes of such void or unenforceable provision.
 
8.            Governing Law .  This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws thereof.
 
 
[Remainder of page intentionally left blank]

 
2


IN WITNESS WHEREOF, Parent, Merger Sub and the Company have caused this Agreement to be executed as of the date first above written.
 

 
OCCULOGIX, INC.
     
     
 
By: 
/s/ Elias Vamvakas
 
Name:  Elias Vamvakas
 
Title:    Chief Executive Officer
     
     
 
OCUSENSE ACQUIRECO, INC.
     
     
 
By:   
/s/ Elias Vamvakas
 
Name:  Elias Vamvakas
 
Title:    Chief Executive Officer
     
     
 
OCUSENSE, INC.
     
     
 
By:   
/s/ Eric Donsky
 
Name:  Eric Donsky
 
Title:    Chief Executive Officer

 
SIGNATURE PAGE TO SECOND AMENDING AGREEMENT
 
 


EXHIBIT 10.2
 
Execution Copy
 
SECOND AMENDING AGREEMENT

THIS SECOND AMENDING AGREEMENT (this “ A greement ”), dated as of October 1, 2008, is made by and among OccuLogix, Inc. (the “ Company ”), a Delaware corporation with executive offices located at 2600 Skymark Avenue, Building 9, Suite 201, Mississauga, Ontario, L4W 5B2, Marchant Securities Inc. (the “Agent” ), an Ontario corporation with offices located at 100 York Boulevard, Suite 404, Richmond Hill, Ontario, L4B 1J8, and the investors listed on the Schedule of Investors attached hereto as Exhibit A (individually, an “Investor” and, collectively, the “Investors” ). 

The Company may be considered a “connected issuer” and/or a “related issuer” (as those terms are defined in National Instrument 33-105—Underwriting Conflicts) of the Agent.  Elias Vamvakas, the Chairman and Chief Executive Officer of the Company, and members of his family have an indirect ownership interest in the Agent as to approximately 32%.  See Section 3.2(p) of the Securities Purchase Agreement (defined below).
 
BACKGROUND
 
A.           Reference is made to the Securities Purchase Agreement, dated as of May 19, 2008, by and among the Company, the Agent and the investors listed on the Schedule of Investors attached as Exhibit A thereto, including the Investors, as amended by the Amending Agreements, each dated as of August 29, 2008, by and among the Company, the Agent and each of the Investors (as amended, the “Securities Purchase Agreement” ).  Pursuant to the Securities Purchase Agreement, the Investors have agreed to purchase, and the Company has agreed to sell, upon the terms and conditions stated therein, $2,173,000 aggregate amount of shares of common stock, par value $.001 per share, of the Company.
 
B.           The Securities Purchase Agreement provides that the Agent’s counsel, Cassels, Brock & Blackwell LLP ( CBB ), would act as escrow agent in connection with the closing of the transactions contemplated by the Securities Purchase Agreement.  CBB has informed the Agent and the Company that it will not act in that capacity.
 
C.           The Securities Purchase Agreement also makes reference to a certain agency agreement between the Agent and the Company.  No formal agency agreement has been, or will be, entered into by the Agent and the Company.
 
D.           The Securities Purchase Agreement, as a result of a drafting error, also makes reference to the terms “Event”, “Event Payment” and “Event Payments”.  None of these terms is relevant or applicable to the Securities Purchase Agreement.
 
E.           The Company, the Agent and the Investors have agreed to amend the Securities Purchase Agreement in order to accommodate the changes in circumstances, described in Recitals B and C, that have occurred since the execution and delivery of the Securities Purchase Agreement and to correct the drafting error described in Recital D.

 
 

 

F.           The Agent has provided each of the Investors with instructions regarding the payment of the Closing Funds (defined below).
 
NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company, the Agent and the Investors hereby agree as follows:
 
1.            Definitions .  In addition to the terms defined elsewhere in this Agreement, capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Securities Purchase Agreement.
 
2.            Definition of “Escrow Agent” .  The definition of “Escrow Agent” in Section 1.1 of the Securities Purchase Agreement is hereby deleted in its entirety.
 
3.            Section 2.2(b) .  Paragraph (b) of Section 2.2 of the Securities Purchase Agreement is hereby deleted in its entirety.
 
4.            Payment of Aggregate Purchase Price .  Each of the Investors hereby agrees to deliver, or cause to be delivered, to the Company, in trust, in United States dollars and in immediately available funds, the aggregate Purchase Price of the number of the Common Shares set forth opposite such Investor’s name on the Schedule of Investors attached as Exhibit A to the Securities Purchase Agreement (the “Closing Funds” ), all in accordance with written instructions provided to such Investor by the Agent, as such instructions may be amended or supplemented in writing from time to time.  The Company shall hold in trust, in a segregated bank account (the “Trust Account” ), for the sole benefit of each of the Investors, the Closing Funds delivered by such Investor to the Company, in trust, pursuant to this Section 4, together with any interest earned thereon in the Trust Account ( “Interest” ), until the Closing.  The Closing Funds and any Interest shall constitute trust property for the purposes for which it is held.  Provided that all of the closing conditions set forth in the Securities Purchase Agreement shall have been satisfied or waived, the Agent shall deliver a direction to the Company, authorizing and directing the Company to release the Closing Funds and any Interest from the trust created hereby, whereupon the Company shall so release the Closing Funds and any Interest and they shall become the sole property of the Company and represent full payment for the number of the Common Shares being purchased by such Investor pursuant to the Securities Purchase Agreement.  Without derogating from the scope of the power and authority granted by each of the Investors to the Agent pursuant to Section 2.3 of the Securities Purchase Agreement, each of the Investors hereby irrevocably authorizes the Agent, in its sole discretion, to deliver such direction to the Company upon the fulfillment of the closing conditions set forth in the Securities Purchase Agreement to the satisfaction of the Agent or the waiver of such closing conditions by the Agent, in each case, in the Agent’s sole discretion and without any further instructions, direction or confirmation of such Investor.

 
2

 

5.            Return of the Closing Funds .  Notwithstanding Section 4 of this Agreement, if, at any time, the Company and the Agent do not have a reasonable expectation that the Closing shall occur on or prior to October 10, 2008 for any reason whatsoever, then the Company shall return to each of the Investors, forthwith, the Closing Funds and any Interest.  In any event, if the Closing does not occur on or prior to October 10, 2008 for any reason whatsoever, then the Company shall return to each of the Investors, forthwith, the Closing Funds advanced by such Investor and any Interest.  In addition, the Company may return to each of the Investors, at any time and for any reason whatsoever, the Closing Funds and any Interest.  In any such case, until such time as the Securities Purchase Agreement, as amended hereby, has been, or may be, terminated pursuant to Section 7.1 thereof, as amended hereby, the Agent may instruct each of the Investors to deliver the Closing Funds to the Company again in accordance with Section 4 of this Agreement.
 
6.            Section 7.1(d) .  Paragraph (d) of Section 7.1 of the Securities Purchase Agreement is hereby deleted in its entirety and replaced with the following paragraph (d):
 
“(d)      automatically on November 12, 2008.”
 
7.            Agency Agreement .  Each of the Investors understands and hereby acknowledges that the Agency Agreement was not entered into by the Agent and the Company.
 
8.            Definition of “Agency Agreement” .  The definition of “Agency Agreement” in Section 1.1 of the Securities Purchase Agreement is hereby deleted in its entirety.
 
9.            Mutatis Mutandis Construction of Securities Purchase Agreement; “Agency Agreement” .  The Securities Purchase Agreement (including, without limitation, Sections 2.3, 3.2(p) and 6.1 thereof) shall be read and construed mutatis mutandis so as to take into account, or reflect, the fact that the Agency Agreement does not exist.
 
10.            Definition of “Event” .  The definition of “Event” in Section 1.1 of the Securities Purchase Agreement is hereby deleted in its entirety.
 
11.            Mutatis Mutandis Construction of Securities Purchase Agreement; “Event Payment” .  The Securities Purchase Agreement (including, without limitation, Sections 6.1(d), 6.2(m) and 6.6 thereof) shall be read and construed mutatis mutandis so as to remove all references to the terms “Event Payment” and “Event Payments”.  Without limiting the generality of the foregoing, the last sentence of Section 6.6 of the Securities Purchase Agreement is hereby deleted in its entirety.
 
12.            Section 3.2(p) .  Notwithstanding part (v) of paragraph (p) of Section 3.2 of the Securities Purchase Agreement, each of the Investors understands and hereby acknowledges that the Agent will not receive any benefit in connection with the Offering, other than the commission payable to the Agent by the Company, as such commission is described in the Company’s Proxy Statement for the 2008 Annual and Special Meeting of Stockholders which was filed with the SEC on August 29, 2008.  Part (v) of paragraph (p) of Section 3.2 of the Securities Purchase Agreement shall be read and construed accordingly.

 
3

 

13.            Securities Purchase Agreement in Full Force and Effect .  The Securities Purchase Agreement remains in full force and effect, unamended, other than as specifically amended by this Agreement.
 
14.            Amendments; Waivers .  No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an amendment, by the Company and the Investors or, in the case of a waiver, by the party against whom enforcement of any such waiver is sought.  No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.
 
15.            Construction .  The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.  The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.
 
16.            Governing Law; Venue; Waiver of Jury Trial .  THE CORPORATE LAWS OF THE STATE OF DELAWARE SHALL GOVERN ALL ISSUES CONCERNING THE RELATIVE RIGHTS OF THE COMPANY AND ITS STOCKHOLDERS.  ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.  THE COMPANY, THE AGENT AND EACH INVESTOR HEREBY IRREVOCABLY SUBMIT TO THE NON-EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN FOR THE ADJUDICATION OF ANY DISPUTE BROUGHT BY THE COMPANY, THE AGENT OR ANY INVESTOR HEREUNDER IN CONNECTION HEREWITH AND HEREBY IRREVOCABLY WAIVE, AND AGREE NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING BROUGHT BY THE COMPANY, THE AGENT OR ANY INVESTOR, ANY CLAIM THAT HE, SHE OR IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT OR THAT SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER.  EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THE SECURITIES PURCHASE AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF.  NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW.  THE COMPANY, THE AGENT AND EACH INVESTOR HEREBY WAIVE ALL RIGHTS TO A TRIAL BY JURY.

 
4

 

17.            Execution .  This Agreement may be executed in any number of separate counterparts (including by facsimile or e-mail transmission), all of which, when taken together, shall be considered one and the same agreement.  In the event that any signature is delivered by facsimile transmission or e-mail attachment, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or e-mail-attached signature page were an original thereof.
 
18.            Severability .  If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Agreement.
 
19.            Currency .  All dollar amounts in this Agreement are expressed in the lawful currency of the U.S.
 
[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

 
5

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
 

 
OCCULOGIX, INC.
 
     
     
  By:  
/s/ Elias Vamvakas
 
 
Name:  Elias Vamvakas
 
 
Title:    Chief Executive Officer
 
     
     
 
MARCHANT SECURITIES INC.
 
     
     
  By:  
/s/ Gregory L. Marchant
 
 
Name:  Gregory L. Marchant
 
 
Title:    President and CEO
 

 
 

 

 
Investor Signature Page
 
By his, her or its execution and delivery of this signature page, the undersigned hereby joins in and agrees to be bound by the terms and conditions of the Second Amending Agreement (the “Agreement” ), dated as of October 1, 2008, by and among OccuLogix, Inc., Marchant Securities Inc. and the investors listed on the Schedule of Investors attached thereto as Exhibit A , and authorizes this signature page to be attached to the Agreement or counterparts thereof.
 

 
Name of Investor:
   
         
         
 
By:
 
   
Name:
   
   
Title:
   
         
 
Address:
 
   
   
   
   
   
   
 
Telephone No.:
 
     
 
Facsimile No.:
 
     
 
Email Address:
 
     
 
Aggregate Purchase Price:  U.S.$
 

 
 

 
 
Exhibit A
 
SCHEDULE OF INVESTORS
 

Investor
Amount of Investment (U.S.$)
     
2016728 Ontario Inc.
100,000
 
Simon Benstead
300,000
 
Paul Bluhm
50,000
 
Timothy Callan
5,000
 
Trevor Callan
10,000
 
Cardinal Crest Holdings, LLC
125,000
 
Cheresh Varner Trust
5,000
 
Marcy Colton
50,000
 
Tom Colton
50,000
 
Michael Cucuz
20,000
 
Sally A. Davidson
350,000
 
Thomas N. Davidson Education Trust – 2006
125,000
 
Thomas N. Davidson Revocable Trust
200,000
 
Justin DiCiano
10,000
 
Ralph W. Goldsilver
25,000
 
Gus and Anne Karnasiotis
60,000
 
Richard L. Lindstrom
100,000
 
Lynchburg Wisdom Ventures, LLC
10,000
 
Rachel Mamounis
18,000
 
New Horizons Holdings Inc.
10,000
 
Peoples International Co. Inc.
40,000
 
Anthony Reisis
50,000
 
Chris Salapoutis
75,000
 
David Sarraf
10,000
 
S.I.F.I. S.p.A.
150,000
 
Syra Kamin Limited
50,000
 
John C. Taylor
25,000
 
Felicia Warheit
25,000
 
Glenn Warheit
25,000
 
Phillip Warheit
100,000
 
 
 


EXHIBIT 99.1
 
 
News Release
For Immediate Release

 
OccuLogix Announces Closing of Transactions
 
Toronto, ON—October 6, 2008— OccuLogix, Inc. (NASDAQ: OCCX; TSX: OC) announced the closing of the acquisition of the minority ownership interest in San Diego-based OcuSense, Inc. that OccuLogix did not already own, the private placement of U.S.$2,173,000 of shares of OccuLogix’s common stock at a per share price of U.S.$0.10, the pre-payment by the Company of its U.S.$6,703,500 aggregate principal amount bridge loan at a per share price of U.S.$0.085 and the payment of U.S.$481,200 of the commission remaining owing for placement agency services rendered by Marchant Securities Inc. at a per share price of U.S.$0.10.  The acquisition of OcuSense common stock involved only common stock consideration, and the pre-payment of the bridge loan and the payment of commission were made by the issuance by the Company of shares of its common stock.  All of these transactions had been approved by the Company’s stockholders at the Annual and Special Meeting of Stockholders on September 30, 2008 and were described in the Company’s proxy statement for the meeting, which is available electronically on EDGAR ( www.sec.gov ) and SEDAR ( www.sedar.com ).

In connection with these transactions, the Company issued an aggregate of 188,401,588   shares of its common stock.  As a result, the Company’s current issued and outstanding share capital consists of 245,707,733 shares of common stock.  As previously announced, OccuLogix intends to effect a 1:25 reverse stock split tomorrow.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.  The securities issued in connection with these transactions have not been registered under the Securities Act of 1933, as amended (the “Act”) or any state securities laws or qualified under any Canadian provincial or territorial securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Act and applicable state securities laws or in Canada absent a valid prospectus, or an applicable exemption from the prospectus requirements, under applicable provincial and territorial securities laws.  The Company has agreed to file a registration statement in the United States covering the resale of certain of the securities issued in connection with the transactions.

As originally contemplated and previously disclosed in the Company’s proxy statement for the meeting, upon the closing of the acquisition of OcuSense, Elias Vamvakas stepped down as OccuLogix’s Chief Executive Officer but remains the Chairman of the Board.  Eric Donsky, OcuSense’s Chief Executive Officer, is now the Chief Executive Officer of OccuLogix.  Mr. Donsky is also a member of the Company’s board of directors.

About OccuLogix, Inc.

OccuLogix ( www.occulogix.com ) is a healthcare company focused on ophthalmic devices for the diagnosis and treatment of age-related eye diseases.

About OcuSense, Inc.

OcuSense ( www.ocusense.com ) is an ophthalmic device company developing and commercializing novel, laboratory-on-a-card technologies that enable eye care practitioners to test for highly sensitive and specific biomarkers in tears at the point-of-care.

Forward-Looking Statements

This press release may contain forward-looking statements.  These statements relate to future events and are subject to risks, uncertainties and assumptions about the Company.  These statements are only predictions based on our current expectations and projections about future events.  You should not place undue reliance on these statements.  Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Forms 10-K and 10-Q.  We do not undertake to update any forward-looking statements.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Suh Kim
(905) 602-0887, ext. 3915
suh.kim@occulogix.com
 
 


EXHIBIT 99.2
 
 
News Release
For Immediate Release
OccuLogix Effects Reverse Stock Split
 
Toronto, ON—October 7, 2008— OccuLogix, Inc. (NASDAQ: OCCX; TSX: OC) announced that it has effected a 1:25 reverse stock split of its common stock, as a result of which every 25 issued and outstanding shares of common stock has been combined into one share.  No fractional share will be issued as a result of the reverse stock split.  Rather, stockholders of the Company will receive a whole share in lieu of any fractional share to which they might otherwise have been entitled.

OccuLogix’s common stock will begin trading on a split-adjusted basis on NASDAQ and the TSX, effective at the open of business on Thursday, October 9, 2008.  The letter “D” will be appended to OccuLogix’s NASDAQ ticker symbol, OCCX, for a period of 20 trading days, after which time the letter “D” will be removed.  The Company’s common stock will also trade under a new CUSIP number.

The reverse stock split affects all of OccuLogix’s issued and outstanding shares of common stock, as well as the number of shares issuable upon the exercise of outstanding stock options and warrants.

The Company’s stockholders of record will receive instructions from the Company’s transfer agent, Mellon Investor Services LLC, regarding the procedures for exchanging their stock certificates in connection with the reverse stock split.  Those stockholders holding their common stock in “street name” will receive instructions from their brokerage firms if they need to take any action in connection with the reverse stock split.

The Company’s board of directors had recommended the reverse stock split, in part, to help the Company regain compliance with the $1.00 minimum bid price requirement for continued listing on NASDAQ.  OccuLogix’s stockholders approved the reverse stock split at the Annual and Special Meeting of Stockholders on September 30, 2008, and the Company’s board of directors set the reverse split ratio at 1:25 on that same day.

About OccuLogix, Inc.

OccuLogix ( www.occulogix.com ) is a healthcare company focused on ophthalmic devices for the diagnosis and treatment of age-related eye diseases.  Its wholly-owned subsidiary, OcuSense, Inc. ( www.ocusense.com ) is an ophthalmic device company developing and commercializing novel, laboratory-on-a-card technologies that enable eye care practitioners to test for highly sensitive and specific biomarkers in tears at the point-of-care.

Forward-Looking Statements

This press release may contain forward-looking statements.  These statements relate to future events and are subject to risks, uncertainties and assumptions about the Company.  These statements are only predictions based on our current expectations and projections about future events.  You should not place undue reliance on these statements.  Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Forms 10-K and 10-Q.  We do not undertake to update any forward-looking statements.


FOR FURTHER INFORMATION, PLEASE CONTACT:

Suh Kim
(905) 602-0887, ext. 3915
suh.kim@occulogix.com